Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 7/20 | 0.55 |
| ▸ | CTNNB1 | P35222 | 7/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18165183 | 0.89 | BCL9 (0.51) | BCL9CTNNB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20021936 | 0.84 | BCL9 (0.53) | BCL9CTNNB1MAPTHSD17B10PDE5A | |
| SCHEMBL20021931 | 0.78 | MGLL (0.60) | BCL9CTNNB1MAPTC5AR1 | |
| SCHEMBL20021941 | 0.78 | CTNNB1 (0.86) | BCL9CTNNB1 | |
| SCHEMBL12907984 | 0.78 | ABL1 (0.45) | BCL9CTNNB1MAPTHSD17B10 | |
| SCHEMBL1136127 | 0.78 | MRGPRX1 (0.48) | CYP1A2CYP2C9CYP2C19MAPTHSD17B10 | |
| SCHEMBL18165105 | 0.77 | ABL1 (0.54) | CYP1A2CYP2C9CYP2C19NPY5R | |
| SCHEMBL1239679 | 0.77 | ABL1 (0.46) | BCL9CTNNB1MAPTHSD17B10PDE5A | |
| SCHEMBL20021940 | 0.77 | CTNNB1 (0.90) | BCL9CTNNB1 | |
| SCHEMBL20021919 | 0.76 | BCL9 (0.54) | BCL9CTNNB1MAPTSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 4/4885CYP1A2 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.